IP Library Granted Patent US 12,636,517
Granted Patent B2
US 12,636,517 · App. 18/169,811 · Granted May 26, 2026

Non-ablative photonic devices and related methods

Inventors: Luis De Taboada (Carlsbad, CA); Brian Pryor (Newark, DE)
Assignee: LiteCure, LLC
A61N5/0625A61N5/062G02B6/4204G02B6/4298A61N2005/0628A61N2005/063A61N2005/0631A61N2005/0651A61N5/067
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,636,517
App. No.
18/169,811
Granted
May 26, 2026
Kind
B2
Abstract

A method of delivering light energy to a pathological tissue includes emitting light energy from a first optical element within a cannula, producing a substantially uniform irradiance profile from the light energy within the cannula, transmitting the light energy emitted from the first optical element through a second optical element in thermal contact with a distal end of the cannula to the pathological tissue without ablating the pathological tissue, and conducting thermal energy from the pathological tissue through the second optical element and to the cannula.

Claims (20)

1 . A method of delivering light energy to the pathological tissue of a mammal at the skin or other external tissue, the method comprising:

emitting first light energy from a first optical element;

producing a substantially uniform first irradiance profile from the first light energy;

transmitting the first light energy along a first optical path from the first optical element through a distal end surface of a second optical element directly, and in a first axial direction, to a surface of the pathological tissue in a non-invasive manner without ablating the pathological tissue;

emitting second light energy from a third optical element;

producing a substantially uniform second irradiance profile from the second light energy; and

transmitting the second light energy along a second optical path from the third optical element through a distal end surface of a fourth optical element directly, and in the first axial direction, to the surface of the pathological tissue in a non-invasive manner without ablating the pathological tissue;

wherein the first light energy and the second light energy do not overlap one another at the surface of the pathological tissue and do overlap one another at a depth below the surface of the pathological tissue.

2 . The method of claim 1 , wherein the first optical element and/or the third optical element comprises an optical fiber and the second optical element and/or the fourth optical element is in direct, non-invasive contact with the surface of the pathological tissue.

3 . The method of claim 1 , wherein the second optical element and/or the fourth optical element comprises a cylindrical sapphire rod.

4 . The method of claim 1 , further comprising generating the first light energy and/or the second light energy with a laser.

5 . The method of claim 1 , further comprising generating the first light energy and/or the second light energy with a light-emitting diode (LED).

6 . The method of claim 1 , wherein the first irradiance profile and/or the second irradiance profile has a non-circular cross-sectional shape.

7 . The method of claim 1 , wherein the first irradiance profile and/or the second irradiance profile has a hexagonal cross-sectional shape or a square cross-sectional shape.

8 . The method of claim 1 , further comprising directing the first light energy through one or more lenses positioned between the first optical element and the second optical element.

9 . The method of claim 8 , further comprising directing the second light energy through one or more lenses positioned between the third optical element and the fourth optical element.

10 . The method of claim 1 , further comprising:

delivering nanoparticles to the pathological tissue such that the nanoparticles accumulate at the pathological tissue;

transmitting the first light energy and the second light energy to the nanoparticles at the pathological tissue; and

heating the nanoparticles with the first light energy and the second light energy to destroy the pathological tissue without harming healthy tissue adjacent to the pathological tissue.

Assignments (1)
SECURITY INTEREST Recorded Jan 3, 2024
From: LITECURE LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 066162/0761 →
Continuity (4)
Division 17303765 · Jun 7, 2021
Continuation 16111735 · Aug 24, 2018
Provisional Application 62552299 · Aug 30, 2017
Related Publication 20230191148A1 · Jun 22, 2023
References Cited (79)
US 1844247A · Freemon · 1932 [cited by applicant]
US 2183726A · Sommer et al. · 1939 [cited by applicant]
US 2490074A · Marty · 1949 [cited by applicant]
US 2699771A · Ruttger-Pelli · 1955 [cited by applicant]
US 4907132A · Parker · 1990 [cited by applicant]
US 5336159A · Cheng · 1994 [cited by applicant]
US 5415652A · Mueller et al. · 1995 [cited by applicant]
US 5591219A · Dungan · 1997 [cited by applicant]
US 6056204A · Glezer et al. · 2000 [cited by applicant]
US 6063108A · Salansky et al. · 2000 [cited by applicant]
US 6066129A · Larson · 2000 [cited by applicant]
US 6214035B1 · Streeter · 2001 [cited by applicant]
US 6413268B1 · Hartman · 2002 [cited by applicant]
US 6620154B1 · Amirkhanian et al. · 2003 [cited by applicant]
US 6866678B2 · Shenderova et al. · 2005 [cited by applicant]
US 6989023B2 · Black · 2006 [cited by applicant]
US 7033382B2 · Lach · 2006 [cited by applicant]
US 7052167B2 · Vandershuit · 2006 [cited by applicant]
US 7083580B2 · Bernabei · 2006 [cited by applicant]
US 7083581B2 · Tsai · 2006 [cited by applicant]
US 7144247B2 · Black · 2006 [cited by applicant]
US 7264598B2 · Shin · 2007 [cited by applicant]
US 7282037B2 · Cho · 2007 [cited by applicant]
US 7335170B2 · Milne et al. · 2008 [cited by applicant]
US 7344528B1 · Tu et al. · 2008 [cited by applicant]
US 7749178B2 · Imboden et al. · 2010 [cited by applicant]
US 7762964B2 · Slatkine · 2010 [cited by applicant]
US 7783346B2 · Smith et al. · 2010 [cited by applicant]
US 8498506B2 · Smith et al. · 2013 [cited by applicant]
US 8574177B2 · Pryor et al. · 2013 [cited by applicant]
US 8685010B2 · McMillan · 2014 [cited by examiner]
US 8882685B2 · Pryor et al. · 2014 [cited by applicant]
US 8968221B2 · Pryor et al. · 2015 [cited by applicant]
US 9358403B2 · Pryor et al. · 2016 [cited by applicant]
US 9649506B2 · Pryor et al. · 2017 [cited by applicant]
US 10238889B2 · Pryor et al. · 2019 [cited by applicant]
US 10675480B2 · Pryor et al. · 2020 [cited by applicant]
US 11020606B2 · Pryor et al. · 2021 [cited by applicant]
US 11033754B2 · De Taboada · 2021 [cited by examiner]
US 11511128B2 · Pryor et al. · 2022 [cited by applicant]
US 20030163068A1 · Kang · 2003 [cited by applicant]
US 20030219202A1 · Loebb et al. · 2003 [cited by applicant]
US 20030232303A1 · Black · 2003 [cited by applicant]
US 20040138727A1 · Taboada et al. · 2004 [cited by applicant]
US 20040193235A1 · Altshuler et al. · 2004 [cited by applicant]
US 20040193236A1 · Altshuler et al. · 2004 [cited by applicant]
US 20040236252A1 · Muzzi et al. · 2004 [cited by applicant]
US 20040260209A1 · Ella et al. · 2004 [cited by applicant]
US 20040260212A1 · Cho · 2004 [cited by applicant]
US 20060235494A1 · Vanderschuit · 2006 [cited by applicant]
US 20060253051A1 · Milne et al. · 2006 [cited by applicant]
US 20070038206A1 · Altshuler · 2007 [cited by examiner]
US 20070073366A1 · Porco · 2007 [cited by applicant]
US 20070096118A1 · Mahalingam et al. · 2007 [cited by applicant]
US 20080014011A1 · Rossen · 2008 [cited by applicant]
US 20080262394A1 · Pryor et al. · 2008 [cited by applicant]
US 20080292255A1 · Stevens et al. · 2008 [cited by applicant]
US 20090001372A1 · Arik et al. · 2009 [cited by applicant]
US 20090234253A1 · Vandenbelt et al. · 2009 [cited by applicant]
US 20090248004A1 · Altshuler et al. · 2009 [cited by applicant]
US 20090299236A1 · Pryor et al. · 2009 [cited by applicant]
US 20100042080A1 · Smith et al. · 2010 [cited by applicant]
US 20100286673A1 · Altshuler · 2010 [cited by examiner]
US 20110144725A1 · Pryor et al. · 2011 [cited by applicant]
US 20130041309A1 · Siegel · 2013 [cited by examiner]
US 20130253487A1 · Liu · 2013 [cited by examiner]
US 20140316387A1 · Harris · 2014 [cited by examiner]
US 20150065925A1 · Pryor et al. · 2015 [cited by applicant]
US 20150174424A1 · Pryor et al. · 2015 [cited by applicant]
US 20150190649A1 · Gelfand · 2015 [cited by examiner]
US 20160279440A1 · Pryor et al. · 2016 [cited by applicant]
US 20170304646A1 · Pryor et al. · 2017 [cited by applicant]
US 20200360713A1 · Pryor et al. · 2020 [cited by applicant]
US 20220016440A1 · Taboada et al. · 2022 [cited by applicant]
WO WO10006082 · 2010 [cited by applicant]
WO WO10060097 · 2010 [cited by applicant]
Kyocera Corporation, 2007, Single crystal sapphire, product brochure, 8 pp. [cited by applicant]
EP Search Report in European App. No. 18851281.8, dated Apr. 23, 2020, 8 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Application No. PCT/US2018/047889, dated Oct. 19, 2018, 12 pages. [cited by applicant]